MDDI

Prenosis Inc. Appoints Leadership Team for Commercialization In Hospitals

Retrieved on: 
Wednesday, October 4, 2023

CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Prenosis, Inc., an artificial intelligence company enabling precision medicine for abnormal immune responses in acute care, announced today the appointment of Robin Carver, RN, MSN, CIC as Vice President, Health System Engagement, Brian Bray as Vice President, Technology, and an expanded role for Carlos Lopez-Espina as Senior Vice President of Research & Development. Prenosis also announced the addition of Pratik Sinha, MD, PhD, to the company's scientific advisory board.

Key Points: 
  • Prenosis also announced the addition of Pratik Sinha, MD, PhD, to the company's scientific advisory board.
  • Carver and Mr. Bray, executives with over 40 years of combined experience in advancing technology in hospitals, will serve on the executive management team and lead the company's expansion in healthcare systems.
  • "Robin, Brian and Carlos' leadership in commercialization, integration and data will add significant value to the company as we enter the next phase of Prenosis' growth," said Reddy.
  • Prenosis developed its core resource--the world's largest biobank and dataset for decoding abnormal immune responses in acute care--in partnership with over eleven U.S. hospitals.

NIH Awards Prenosis With Two Grants Totaling $4.8 million to Enable Precision Medicine for Sepsis

Retrieved on: 
Wednesday, July 12, 2023

CHICAGO, July 12, 2023 /PRNewswire/ -- Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis's Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients' health states rapidly evolve in acute care environments.

Key Points: 
  • Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime.
  • The goal is to better understand how patients' health states rapidly evolve in acute care environments.
  • The outcomes of these studies could usher in a new era of predictive diagnostics, clinical decision support tools, improved clinical trials, and precision medicine drugs for sepsis.
  • Prenosis generates deep biological profiles of each patient by measuring critical sepsis biomarkers in its Biological Safety Level 2 lab in Chicago.

Prenosis Inc. Receives BARDA Contract to Study Utility of Its Sepsis Diagnostic Tool

Retrieved on: 
Wednesday, June 7, 2023

CHICAGO, June 7, 2023 /PRNewswire/ -- Prenosis Inc., an artificial intelligence company enabling precision medicine in acute care, announced today it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency.

Key Points: 
  • Prenosis has built a large, rapidly growing dataset and biobank from patients with sepsis and other infections.
  • By leveraging its proprietary dataset and AI/ML techniques, Prenosis is creating precision medicine solutions, starting with a sepsis diagnostic tool.
  • Prenosis' Sepsis ImmunoScore™ intends to enable true precision medicine for infection in hospitals.
  • The Sepsis ImmunoScore™ is a pathogen-agnostic, host-based digital diagnostic (HBD) that uses clinical parameters and protein biomarkers to assess a patient's risk of sepsis within 24 hours.

Prenosis Named A Finalist For Hearst Health Prize

Retrieved on: 
Thursday, October 27, 2022

CHICAGO, Oct. 27, 2022 /PRNewswire/ -- Prenosis Inc., a precision medicine company, is one of three finalists for the 2022 Hearst Health Prize, a $100,000 award given in recognition of excellence in data science for managing or improving health in the United States. The competition—offered by the UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data and technologies, and Hearst Health, a division of Hearst and leader in care guidance— evaluates data science projects or programs that have been implemented and have demonstrated improved health outcomes.

Key Points: 
  • CHICAGO, Oct. 27, 2022 /PRNewswire/ -- Prenosis Inc. , a precision medicine company, is one of three finalists for the 2022 Hearst Health Prize, a $100,000 award given in recognition of excellence in data science for managing or improving health in the United States.
  • "We're honored to be recognized by the Hearst Health Prize for our precision medicine platform and sepsis solution," said Bobby Reddy, Jr., Prenosis CEO.
  • "The Hearst Health Prize is one of the world's most important awards for healthcare data science.
  • As the official partner of the Hearst Health Prize, the UCLA Center for SMART Health identifies data science programs making a measurable difference in human health.

Smart-C, World's First Hyper-Portable Surgical Imaging System, Receives Prestigious Medical Device Design Award

Retrieved on: 
Monday, April 18, 2022

The Smart-C, by Turner Imaging Systems, has received the 2022 Medical Design Excellence Awards (MDEA) Silver Medal in the category of Radiological, Imaging, and Electromechanical Devices.

Key Points: 
  • The Smart-C, by Turner Imaging Systems, has received the 2022 Medical Design Excellence Awards (MDEA) Silver Medal in the category of Radiological, Imaging, and Electromechanical Devices.
  • This is the medtech industrys premier award program to honor achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
  • Healthcare systems are under enormous strain and the novel Smart-C design challenges the choke-point of traditional diagnostic and surgical imaging.
  • ABOUT TURNER IMAGING SYSTEMS: Turner Imaging Systems develops and markets X-ray imaging systems that give the user the ability to acquire X-ray images wherever and whenever they are needed.

Anuncia Medical honored as participant in the 2022 Flinn Foundation Bioscience Entrepreneurship Program

Retrieved on: 
Wednesday, March 30, 2022

SCOTTSDALE, Ariz., March 30, 2022 /PRNewswire/ -- Anuncia Medical, Inc., a medtech startup developing neurotherapeutic devices for treatment of hydrocephalus and other neurological disorders, has been selected as one of seven Arizona early-stage bioscience companies to participate in the 2022 Flinn Foundation Bioscience Entrepreneurship Program. A total of 54 Arizona bioscience firms have been selected for this highly competitive program since 2014 and awarded almost $1.6 million in non-dilutive funding.

Key Points: 
  • SCOTTSDALE, Ariz., March 30, 2022 /PRNewswire/ --Anuncia Medical, Inc., a medtech startup developing neurotherapeutic devices for treatment of hydrocephalus and other neurological disorders, has been selected as one of seven Arizona early-stage bioscience companies to participate in the 2022 Flinn Foundation Bioscience Entrepreneurship Program.
  • A total of 54 Arizona bioscience firms have been selected for this highly competitive program since 2014 and awarded almost $1.6 million in non-dilutive funding.
  • Anuncia Medical is honored to be a part of this elite group, furthering the Flinn Foundation's goal of creating a "hub of bioscience entrepreneurs and new enterprises across Arizona."
  • To learn more about the Flinn Foundation Bioscience Entrepreneurship Program, visit www.flinn.org/entrepreneur .